Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2023-02-05 Report Publication Anno…
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Half Year Results Announcement Details 1 page 93.1K
Report Publication Announcement Classification · 95% confidence The document is an ASX announcement dated 6 February 2023, providing details about the upcoming FY23 half year results announcement scheduled for 24 February 2023. It includes information about a broadcast with the CEO and CFO following the results release. The document does not contain actual financial data or the results themselves, but rather announces the timing and details of the forthcoming half year financial results and related investor call. The document length is short (1660 characters), and it serves as a notice or announcement rather than the report itself. According to the classification rules, announcements about the timing or release of reports without the actual report content should be classified as Report Publication Announcement (RPA).
2023-02-05 English
Notification regarding unquoted securities - MVP 7 pages 30.9KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities, specifically performance rights issued under an employee incentive scheme. It details the number of securities issued, the nature of the securities, and compliance with ASX listing rules. There is no financial performance data, earnings information, or management discussion. The document is an announcement about a capital change related to securities issuance. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive notification of securities issuance.
2023-01-19 English
Notification of cessation of securities - MVP 4 pages 24.2KB
Share Issue/Capital Change Classification · 95% confidence The document is a notification about the cessation of securities, specifically options that have expired without exercise or conversion. It provides details about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement related to changes in the company's issued capital securities but does not describe a new share issue or capital increase. It is not a full financial report, earnings release, or management report. It is also not a director's dealing or major shareholding notification. The content fits best with announcements about changes in capital structure or securities status, which aligns with the category 'Share Issue/Capital Change' (SHA). Although the document is about cessation (expiry) of securities rather than issuance, this category covers capital changes including cessation or expiry of securities. The document length is under 5,000 characters and is a direct announcement, not a report publication or certification. Therefore, the best classification is SHA with high confidence.
2023-01-19 English
China Clinical Trials Discontinued 1 page 100.1KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 18 January 2023 regarding the discontinuation of clinical trials in China by Medical Developments International Ltd. It discusses strategic priorities, financial impacts related to contract termination income and impairment, and future plans. The document is relatively short (2484 characters) and serves as a corporate update rather than a detailed financial report or earnings release. It does not contain comprehensive financial statements or detailed quarterly results, nor is it a regulatory certification or voting result. The content fits best as a Capital/Financing Update (CAP) because it discusses financial impacts related to contract termination and impairment, which affect the company's capital and financial position, and strategic resource allocation. Therefore, the appropriate classification is CAP with high confidence.
2023-01-17 English
Annual General Meeting - Recording available 1 page
AGM Information Classification · 95% confidence The document is a short announcement dated 28 October 2022 from Medical Developments International Limited. It informs shareholders and interested parties about the availability of a recording of the Annual General Meeting held on 27 October 2022, providing a link to access it. The document does not contain the AGM materials themselves, financial data, or detailed reports, but rather directs readers to the recording. Given the short length (825 characters) and the nature of the content (announcement of availability of AGM recording), this fits the category of AGM Information (AGM-R).
2022-10-27 English
Chair and CEO Address to Shareholders 5 pages 195.2KB
AGM Information Classification · 95% confidence The document is a detailed address by the Chair and CEO to shareholders at the Annual General Meeting (AGM) held on 27 October 2022. It includes reflections on the company's performance over the past year, strategic updates, financial highlights, leadership changes, and future plans. The content is typical of presentations or speeches delivered during an AGM rather than a formal annual report or financial statement. The document does not contain full financial statements or detailed financial analysis but focuses on operational and strategic updates to shareholders at the AGM. Therefore, the document fits the category of AGM Information (AGM-R). The document length (13,708 characters) supports that it is a full address rather than a brief announcement or regulatory filing.
2022-10-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.